Riklund K E, Makiya R, Sundström B, Bäck O, Henriksson R, Hietala S O, Stigbrand T
Department of Diagnostic Radiology, University of Umeå, Sweden.
Anticancer Res. 1991 Mar-Apr;11(2):555-60.
The radiommunotherapeutic potential of 125I-labeled monoclonal antibodies was investigated in 48 nude mice (BALB/c, nu/nu) inoculated s.c. with the HeLa Hep 2 human adenocarcinoma cell line. This isotope, 125I, which is not commonly used for therapeutic purposes caused significant decrease in tumour growth from day 10 to day 42, when coupled to monoclonal antibodies directed against placental alkaline phosphatase (H7) or cytokeratins (TS1). The average growth rate was approximately 50-60% of that observed in the untreated control group after 42 days. The specific radioactivity in each organ 42 days after injection of radiolabeled monoclonal antibodies, indicated that these target antigens retain significant amounts of radiolabeled antibody in the tumours for at least 6 weeks after injection. No weight loss was seen in the animals during this experiment. By use of autoradiographic techniques, the labeled monoclonal antibodies were visualized deep in tumours in characteristic patterns representative of viable tumour cells (H7) and necrotic areas (TS1). The therapeutic approach using 125I labeled antibodies is encouraging and may offer new dimensions in radioimmunotherapy.
在48只皮下接种了HeLa Hep 2人腺癌细胞系的裸鼠（BALB/c，nu/nu）中研究了¹²⁵I标记的单克隆抗体的放射免疫治疗潜力。这种通常不用于治疗目的的同位素¹²⁵I，当与针对胎盘碱性磷酸酶（H7）或细胞角蛋白（TS1）的单克隆抗体偶联时，从第10天到第42天可使肿瘤生长显著减缓。42天后，平均生长速率约为未治疗对照组的50%-60%。注射放射性标记单克隆抗体42天后，各器官的比放射性表明，这些靶抗原在注射后至少6周内在肿瘤中保留了大量放射性标记抗体。在该实验过程中未观察到动物体重减轻。通过放射自显影技术，标记的单克隆抗体在肿瘤深处以代表存活肿瘤细胞（H7）和坏死区域（TS1）的特征性模式显现出来。使用¹²⁵I标记抗体的治疗方法令人鼓舞，可能为放射免疫治疗提供新的方向。
